Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Powell

Showing results (61-70 of 105) with videos related to

Pageof 11
Sort By:
Science Signaling|February 3, 2026
Decoding cytokine networks in ulcerative colitis to identify pathogenic mechanisms and therapeutic targetsMarton Olbei, Isabelle Hautefort, John P Thomas, et al.
Journal of Crohn'S & Colitis|September 2, 2025
Faecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response: Results from the FAVOUR studyMark A Samaan, Georgina Cunningham, Samuel Hsiang Lim, et al.
Journal for Immunotherapy of Cancer|April 5, 2024
Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitisCathrin L C Gudd, Eoin Mitchell, Stephen R Atkinson, et al.
Immunity|October 16, 2012
The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cellsNick Powell, Alan W Walker, Emilie Stolarczyk, et al.
Journal of Crohn'S & Colitis|May 4, 2025
ECCO Topical Review on Predictive Models on Inflammatory Bowel Disease Disease Course and Treatment ResponseJulien Kirchgesner, Bram Verstockt, Michel Adamina, et al.
Frontline Gastroenterology|July 27, 2018
Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centresMark A Samaan, Polychronis Pavlidis, Jonathan Digby-Bell, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitisNick Powell, Hajir Ibraheim, Tim Raine, et al.
European Journal of Immunology|January 29, 2022
A population of naive-like CD4<sup>+</sup> T cells stably polarized to the T<sub>H</sub> 1 lineageJonathan W Lo, Maria Vila de Mucha, Stephen Henderson, et al.
Annals of Gastroenterology|March 5, 2020
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experienceHajir Ibraheim, Mark A Samaan, Ashish Srinivasan, et al.
Nature Communications|November 4, 2024
CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent mannerJonathan W Lo, Jan-Hendrik Schroeder, Luke B Roberts, et al.
Pageof 11

Showing results (61-70 of 105) with videos related to

Sort By:
Pageof 11
Science Signaling|February 3, 2026
Decoding cytokine networks in ulcerative colitis to identify pathogenic mechanisms and therapeutic targetsMarton Olbei, Isabelle Hautefort, John P Thomas, et al.
Journal of Crohn'S & Colitis|September 2, 2025
Faecal loss of vedolizumab is associated with UC severity, lower serum vedolizumab levels and rates of clinical response: Results from the FAVOUR studyMark A Samaan, Georgina Cunningham, Samuel Hsiang Lim, et al.
Journal for Immunotherapy of Cancer|April 5, 2024
Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitisCathrin L C Gudd, Eoin Mitchell, Stephen R Atkinson, et al.
Immunity|October 16, 2012
The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cellsNick Powell, Alan W Walker, Emilie Stolarczyk, et al.
Journal of Crohn'S & Colitis|May 4, 2025
ECCO Topical Review on Predictive Models on Inflammatory Bowel Disease Disease Course and Treatment ResponseJulien Kirchgesner, Bram Verstockt, Michel Adamina, et al.
Frontline Gastroenterology|July 27, 2018
Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centresMark A Samaan, Polychronis Pavlidis, Jonathan Digby-Bell, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitisNick Powell, Hajir Ibraheim, Tim Raine, et al.
European Journal of Immunology|January 29, 2022
A population of naive-like CD4<sup>+</sup> T cells stably polarized to the T<sub>H</sub> 1 lineageJonathan W Lo, Maria Vila de Mucha, Stephen Henderson, et al.
Annals of Gastroenterology|March 5, 2020
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experienceHajir Ibraheim, Mark A Samaan, Ashish Srinivasan, et al.
Nature Communications|November 4, 2024
CTLA-4 expressing innate lymphoid cells modulate mucosal homeostasis in a microbiota dependent mannerJonathan W Lo, Jan-Hendrik Schroeder, Luke B Roberts, et al.
Pageof 11